Activation of WNT / β-Catenin Signaling in Pulmonary Fibroblasts by TGF-β1 Is Increased in Chronic Obstructive Pulmonary Disease
2011

WNT/β-Catenin Signaling in COPD Lung Fibroblasts

Sample size: 18 publication 10 minutes Evidence: moderate

Author Information

Author(s): Baarsma Hoeke A., Spanjer Anita I. R., Haitsma Gertruud, Engelbertink Lilian H. J. M., Meurs Herman, Jonker Marnix R., Timens Wim, Postma Dirkje S., Kerstjens Huib A. M., Gosens Reinoud

Primary Institution: University of Groningen, Groningen, The Netherlands

Hypothesis

The study investigates the role of WNT/β-catenin signaling in pulmonary fibroblasts of individuals with and without chronic obstructive pulmonary disease (COPD).

Conclusion

The WNT/β-catenin pathway is activated in pulmonary fibroblasts in response to TGF-β1, and this activation is significantly enhanced in fibroblasts from COPD patients.

Supporting Evidence

  • Pulmonary fibroblasts expressed mRNA of genes required for WNT signaling.
  • TGF-β1 induced higher expression of WNT-5B, FZD6, and FZD8 mRNA in fibroblasts from individuals with COPD.
  • TGF-β1 activated β-catenin signaling, increasing total and transcriptionally active β-catenin protein expression.
  • Fibroblasts from COPD patients showed enhanced fibronectin deposition in response to TGF-β1.

Takeaway

This study shows that a specific signaling pathway in lung cells is more active in people with a lung disease called COPD, which might help us understand how to treat it better.

Methodology

The study assessed WNT-pathway gene expression and the functional role of β-catenin using human lung fibroblasts and primary fibroblasts from individuals with and without COPD.

Potential Biases

The study's findings may be influenced by the age differences between the COPD groups and controls.

Limitations

The study does not provide insight into the effect of smoking on WNT pathway gene expression by fibroblasts due to the lack of a separate non-smoking control group.

Participant Demographics

The study included 18 individuals: 7 controls, 5 with COPD stage II, and 6 with COPD stage IV, with a mix of genders and smoking histories.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0025450

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication